Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated GI Damage - Synchronise

Study identifier:N13

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

SYNCHRONISE: Esomeprazole 20 mg once daily for relief of upper gastrointestinal Symptoms associated with continuous use of NSAIDs including COX-2 selective NSAIDs in Dutch General Practice: The influence of Risk-factors for NSAID-associated GI damage on sympton response

Medical condition

Heartburn

Phase

-

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

1220

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 Jan 2006
Primary Completion Date: 01 Mar 2007
Study Completion Date: 01 Oct 2007

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria